MET and non-small cell lung carcinoma: Despite that newer MET-TKIs such as Capmatinib, Savolitinib, Tepotinib, and Cabozantinib have been investigated in EGFRm+ NSCLC patients with acquired MET amplification [22,28,29,30], Crizotinib remains the most available therapeutic option for these patients.